Fathom Holdings Prices Underwritten Public Offering of Common Stock CARY, N.C., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. After the underwriting dis...
Fathom Holdings Announces Proposed Offering of Common Stock CARY, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform, today announced a proposed primary offering of its common stock in an underwritten public offering. The Company also expects to grant to the underwriters of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. The offering is subject to market and other conditions, and ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 2, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in conne...
PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT), as previously announced on July 14, 2025, declared its monthly distribution for September 2025 of $0.08 per share, payable on September 30, 2025 to stockholders of record as of September 15, 2025. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distributions will be reported to stockholders on Form 1099 after the end of the cal...
A director at Westlake Chemical Partners Lp bought 7,462 shares at 21.877USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Fathom to Present at the 2025 Gateway Conference on September 4th CARY, N.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. (Nasdaq: FTHM) (“Fathom” or the “Company”), a national, technology-driven, end-to-end real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings for brokerages and agents, will participate in the , which is being held September 3-4, at the Four Seasons Hotel in San Francisco, CA. Fathom CEO Marco Fregenal is scheduled to present on Thursday, September 4, at 10:00 am Pacific Time (PT). The presentation will be webcas...
A director at Agree Realty Corp bought 4,850 shares at 72.150USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in Part A of REVEAL Phase 1/2 trials as of August 2025 data cutoff Part A data from REVEAL Phase 1/2...
PennantPark Investment Corporation Announces Financial Results for the Quarter Ended June 30, 2025 MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) announced today its financial results for the third quarter ended June 30, 2025. HIGHLIGHTS Quarter ended June 30, 2025 (unaudited)($ in millions, except per share amounts) Assets and Liabilities: Investment portfolio (1) $1,171.6 Net assets $480.6 Net asset value per share $7.36 Quarterly change in net asset value per share (1.6)% Credit Facility $31...
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, ...
PennantPark Investment Corporation Announces Monthly Distributions of $0.08 per Share MIAMI, Aug. 04, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT), as previously announced on July 14, 2025, declared its monthly distribution for August 2025 of $0.08 per share, payable on September 2, 2025 to stockholders of record as of August 15, 2025 and declared its monthly distribution for September 2025 of $0.08 per share, payable on September 30, 2025 to stockholders of record as of September 15, 2025. The distributions are expected to be paid from taxable ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employm...
PennantPark Investment Corporation’s Unconsolidated Joint Venture, PennantPark Senior Loan Fund, LLC Completes the Partial Refinancing of its $300 Million Securitization, Lowering the Cost of Financing MIAMI, July 23, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the “Company”) (NYSE: PNNT) today announced that PennantPark Senior Loan Fund, LLC (“PSLF”) through PSLF’s wholly-owned and consolidated subsidiary, PennantPark CLO VII, LLC (“CLO VII”) has closed the partial refinancing of its $300 million debt securitization. The partial refinancing of this securitization (the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.